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Abstract——The microbiome plays a key role in
health and disease, and there has been considerable
interest in therapeutic targeting of the microbiome as
well as mining this rich resource in drug discovery
efforts. However, a growing body of evidence suggests
that the gut microbiota can itself influence the actions
of a range of xenobiotics, in both beneficial and poten-
tially harmful ways. Traditionally, clinical studies eval-
uating the pharmacokinetics of new drugs have mostly
ignored the important direct and indirect effects of the
gut microbiome on drug metabolism and efficacy. De-
spite some important observations from xenobiotic
metabolism in general, there is only an incomplete un-
derstanding of the scope of influence of the microbiome
specifically ondrugmetabolismandabsorption, andhow
this might influence systemic concentrations of parent
compounds and toxic metabolites. The significance of
both microbial metabolism of xenobiotics and the
impact of the gut microbiome on host hepatic enzyme
systems is nonetheless gaining traction and presents a
further challenge in drug discovery efforts, with impli-
cations for improvingtreatmentoutcomesorcounteracting
adverse drug reactions. Microbial factors must now be
considered when determining drug pharmacokinetics
and the impact that anevolvinganddynamicmicrobiome
could have in this regard. In this review, we aim to
integrate the contribution of the gut microbiome in
health and disease to xenobiotic metabolism focusing
on therapeutic interventions, pharmacological drug
action, and chemical biotransformations that collec-
tively will have implications for the future practice of
precision medicine.
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I. Introduction
The principles of xenobiotic metabolism, which is de-
fined as the metabolism of ingested exogenous molecules,
emphasize the role of the liver as the predominant site
of biotransformation after ingestion by the host. Within
this convention, the liver is anatomically,morphologically,
and physiologically specialized as a metabolic organ
and unrivalled inmetabolic capacity in comparisonwith
extrahepatic host sites of chemical transformation
(Michalopoulos, 2007). This viewpoint overlooks the
fact that before orally delivered compounds reach the
liver, an increasing number are first exposed to the gut
microbiota and their associated collection of metabolic
enzymes (which exceeds the repertoire of the liver)
(Li et al., 2014). Indirectly, metabolites produced by the
gut microbiome can also tune the expression and func-
tion of key liver enzymes such as those in the pivotal
cytochrome P450 (CYP) superfamily. Thus, the metabo-
lismofmany clinically useddrugs is likely to be influenced
by either direct or indirect effects of the gut microbiome.
In this review, we first outline the current knowledge
of the gut microbiome in health and disease before
focusing on the metabolic activities associated with this
community of microbes residing in the gastrointestinal
tract and their aggregate genomes. The collective direct
and indirectmetabolic influence of thesemicrobes in the
gastrointestinal tract is evaluated with regard to the
chemical modification of pharmaceutical compounds,
dietary components, and environmental agents, and the
implications for host health. This is considered within
the context of our expanding knowledge of the role
played by the gut microbiota in health and disease,
host–microbial interactions, and the reciprocal relation-
ship between xenobiotics and the gut bacteria involved
in their metabolism. We also discuss the potential
therapeutic implications arising from these observa-
tions before providing recommendations to guide a
currently neglected but growing area of research toward
therapeutic dividends and the improvement of human
health.
II. The Gut Microbiome
The gastrointestinal tract is inhabited by a vast array
of microbes—bacteria, fungi, yeasts, archaea, and
viruses—termed the gut microbiota (Grenham et al.,
2011). The bacterial division of this consortium is best
studied and reaches the highest density in the large
intestine, with recent estimates of 1013 bacterial cells in
the human colon (Sender et al., 2016a,b). This abun-
dance reflects the optimal bacterial growth conditions
in the large intestine, with amean pH of 6.4 to 7, and the
high density of bacteria residing there in turn confers
this region with a lower redox potential (Sousa et al.,
2008). The large intestine is thus an important host
site for microbial metabolism, a convenient truth that
fortunately aligns with our reliance on the analysis of
stool samples to gain insights into our microbial
inhabitants (Fraher et al., 2012; Claesson et al., 2017).
However, these samples are not representative of the
microbiome of more proximal regions of the large
intestine, and the nonuniform localization and spatial
organization of the gut microbiota along the gastroin-
testinal tract require further evaluation in terms of the
functional implications for microbial xenobiotic metab-
olism (Tropini et al., 2017). This overreliance on fecal
samples, due in part to ease of collection and availabil-
ity, means we still have an incomplete understanding of
the impact of microbial activity in different regions of
the gastrointestinal tract and the implications of region-
specific microbial metabolism for health and disease.
For example, metabolism of dietary methylamines also
occurs in the small intestine with differential profiles of
caecal and fecal metabolism (Hoyles et al., 2018b).
Moreover, microbes in the small intestine may be an
important site for lipid metabolism (Martinez-Guryn
et al., 2018) and are enriched in functions specific for the
metabolism of simple carbohydrates (Zoetendal et al.,
2012; Stremmel et al., 2017).Neither is the gutmicrobiota
homogenous moving from the lumen to the mucosa,
instead existing as a type of gradient with colonic
mucosa-associated and luminal microbial communities
potentially giving rise to niche metabolic capabilities
even at seemingly geographically identical gastrointes-
tinal sites (Galley et al., 2014; Donaldson et al., 2016).
One recent example of this pertains to the mucin
utilizer, Peptostreptococcus russellii, which produces
indoleacrylic acid from tryptophan, important for the
promotion of enhanced intestinal epithelial barrier
function and the suppression of host inflammation
(Wlodarska et al., 2017). Microbial enzymes residing in
the gut lumen can in turn, for example, deconjugate
conjugated cathecholamines with ensuing physiologic
implications for colonic function such aswater transport
(Asano et al., 2012).
Focusing on actual numbers and relative abundances
of bacterial cells frequently obscures the importance of
their collective genome in the gut ecosystem—the gut
microbiome. With an aggregate gene catalog exceeding
the human genome by more than a factor of 100 (Qin
et al., 2010), the gut microbiome exhibits a diverse
functional repertoire, and the encoded metabolic activ-
ities of thesemicrobial genes equate to a largemetabolic
capacity far in excess of its counterpart host genome
(Lynch and Pedersen, 2016). According to both 16S
rRNA gene sequencing and metagenomic shotgun
ABBREVIATIONS: 5-ASA, 5-aminosalicylate; 5-FU, 5-fluorouracil; CYP, cytochrome P450; IBD, inflammatory bowel disease; miRNA,
microRNA; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; PUFA, polyunsaturated fatty acid; TMA,
trimethylamine; TMAO, TMA-N-oxide.
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sequencing of stool samples, the composition of the
adult gut microbiota is dominated by the phyla Firmi-
cutes, Actinobacteria, and Bacteroidetes with lower
relative abundances of Verrucomicrobia and Proteobac-
teria (Zhernakova et al., 2016). Although the interindi-
vidual variation inmicrobiota composition is considerable
such that an accurate definition of the precise composition
of a healthy human microbiota remains elusive, recent
evidence supports a shared global core microbiota
consisting of 14 different genera with medication use
making an important contribution to microbiota com-
positional variation (Falony et al., 2016). It should be
noted that there remains to be a consensus on actual
membership of the core taxapresent in thegutmicrobiome,
and different sequencing and analysis approaches will
give different results. The study by Falony et al. (2016)
also looked at different populations than earlier studies
by Turnbaugh et al. (2009) and Qin et al. (2010).
In contrast to this interindividual variation, a typical
healthy adult gut microbiota is characterized by both
high compositional diversity and stability (Clarke et al.,
2014b). Unlike the host genome, the gut microbiome is
readily modifiable (e.g., by diet or antibiotic usage), and
this can have important implications for expansion or
contraction of its metabolic functions. Prebiotics such as
short chain fructooligosaccharides can promote the
production of equol, an isoflavandiol nonsteroidal es-
trogen of importance in cardiovascular, bone, and men-
opausal health, and whose production varies depending
onmicrobiota composition (Setchell et al., 2002). Amore
extreme example of the modifiable nature of the gut
microbiome lies in the transfer of bacterial genes
encoding porphyranases, agarases, and associated pro-
teins from marine red algae to bacteria residing in the
gastrointestinal tract of Japanese individuals as a
consequence of their seaweed consumption (Hehemann
et al., 2010). Unfortunately, the flip side of this coin—loss
of function—is most likely the more common scenario,
and the low-fiber Western diet is held partially respon-
sible for the lower diversity and the possible extinction of
important taxa from the gut microbiota of Western
populations (Sonnenburg et al., 2016). Reducedmicrobial
gene richness is common in a range of metabolic and
hepatic diseases, with inflammation (Cotillard et al.,
2013; Le Chatelier et al., 2013; Qin et al., 2014; Hoyles
et al., 2018a) and oxygen availability/gradients playing an
important role (Albenberg et al., 2014; Schmidt and Kao,
2014; Friedman et al., 2018). The collateral damage
inflicted by excessive or inappropriate antibiotic usage
on gut microbiota composition is another example
currently being debated (Blaser, 2016).
Despite these concerns over under-represented mi-
crobes and/or reduced microbial gene richness, the
importance of the dictum that structure begets function
for the role of gut microbiota composition in xenobiotic
metabolism is difficult to gauge given that members of
this bacterial ecosystem may exhibit both functional
redundancy and pleiotropy (Clarke et al., 2014b; Moya
and Ferrer, 2016). As indicated above, colonization of
bacteria increases to highest levels in the large intestine
such that sites with a higher exposure to xenobiotics in
fact may have a lower potential for microbial metabo-
lism, such as the small intestine. However, this needs to
be considered in context of the less well studied small-
intestinal microbiota, due in part to the difficulty in
obtaining relevant samples.
Consideration of the gut microbiome and xenobiotic
metabolism also needs to take account of the variation
of the gut microbiome at the extremes of life in
comparison with the reported stability during adult-
hood in healthy individuals. Data indicate a narrowing
of diversity and distinctive microbiota configurations
associated with ageing in long-stay care individuals
compared with that of community dwellers (Claesson
et al., 2012; Jeffery et al., 2016). This is a time of life
with high parallel medication and dietary supplement
consumption, although adverse health events are rarely
considered with regard to this narrowing microbiota
diversity (O’Dwyer et al., 2016; Walsh et al., 2016;
Locquet et al., 2017). Conversely, but equally impor-
tant, the infant gut is largely thought to be sterile in
utero and colonized during birth and postnatally with a
trajectory toward an adult-like complexity taking ap-
proximately 3 years (Clarke et al., 2014a; Perez-Munoz
et al., 2017). There is also a divergence in intestinal
microbiome assembly between different birth modes
(Bokulich et al., 2016), between breast- and formula-fed
infants (Clarke et al., 2014a), and between preterm and
full-term infants, with implications for the associated
microbial metabolite profile (Hill et al., 2017). Other
important factors include the antibiotic usage in early
life (Bokulich et al., 2016; Korpela et al., 2018) and
malnutrition (Million et al., 2017). Of course, during
adulthood there are also a number of factors that shape
or distort the gut microbiome in the colonic meta-
bolic niche, reviewed in detail elsewhere, such as diet
(Portune et al., 2017; Sandhu et al., 2017; Shanahan
et al., 2017), exercise (Campbell and Wisniewski, 2017;
Barton et al., 2018), geographical location (Dikongue
and Segurel, 2017; Quigley, 2017), host genetics
(Kurilshikov et al., 2017), and the experience of stress
(Moloney et al., 2014; Martin and Mayer, 2017). The
ability of the gut microbiome to remodel and persist in
the face of insults such as antibiotic use is probably only
matched in the host by the regenerative capacity of the
liver (Michalopoulos, 2007) (Fig. 1, A and B).
III. Biochemistry of Gut Microbiome
Xenobiotic Metabolism
Although the collective metabolic activity of the gut
microbiome is just beginning to be appreciated with the
emergence and growth of the pharmacomicrobiomic
concept (Saad et al., 2012; ElRakaiby et al., 2014), the
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role of individual microorganisms in drug metabolism
has long been studied (de la HUERGA and Popper,
1951; Smith and Rosazza, 1974). This was largely in the
context of using microbial models to understand mam-
malian drug metabolism and with the ambition of using
microorganisms for the scalable production of drug
metabolites (Murphy, 2015). In contrast to mammalian
CYPs, which are usually membrane-bound and heme-
containing enzymes, many bacterial CYPs are soluble
(Jezequel, 1998). Genome sequencing of Streptomyces
and Bacillus spp. highlighted multiple CYP genes with
subsequent culture-based investigations indicating, for
example, the production of hydroxylated and amidated
metabolites from the nonsteroidal anti-inflammatory
drug (NSAID) flurbiprofen that both overlapped with,
and were distinct from, the mammalian metabolites
(Bright et al., 2011). Enzyme induction was also a noted
feature in individual bacterial strains with a CYP-
dependent fatty acid monooxygenase from Bacillus
megaterium strongly inducible by phenobarbital (Narhi
and Fulco, 1986). Biotransformation of warfarin by
Streptomyces rimosus has also been reported (Cannell
et al., 1997), whereas the reduction of warfarin to
its corresponding alcohol by Nocardia coralline is a
stereoselective reaction (Davis and Rizzo, 1982). Of
course not all of these bacteria are found in the human
gastrointestinal tract, and it has been noted that even in
cases where they are, we cannot assume equivalent
metabolizing activities achieved under specific labora-
tory culture conditions will be recapitulated in the more
dynamic ecological conditions of the gastrointestinal
tract (Jezequel, 1998). They do, however, offer a window
into the metabolic potential that resides in the gut
microbiome as well as hinting at the implications for
drug metabolism and host response. Traditionally,
consideration of these clinical implications in terms of
pharmacokinetics and therapeutic response was largely
confined to drugs undergoing enterohepatic circulation
(Roberts et al., 2002; Spanogiannopoulos et al., 2016).
The principle of microbiota-mediated drug-conjugate
Fig. 1. (A) Metabolic niches in the gut microbiome. The localization and spatial organization of the gut microbiota are not uniform along the
gastrointestinal tract. This dynamic gut ecosystem consists of many unique features, such as microniches, pH gradients, and dynamic microbe–tissue
interactions of relevance for microbial biotransformations. The highest density of bacteria is present in the large intestine, with recent estimates of 1013
bacterial cells in the large intestine associated with microbial genes encoding a broad range of enzymes necessary for xenobiotic biotransformation.
These bacteria are likely most important for pharmacomicrobiomics and reside in a reaction chamber with a mean pH of 6.4–7 and a lower redox
potential than other gastrointestinal niches. Oxygen partial pressures along the gastrointestinal tract also contribute to these metabolic niches. (B)
Factors affecting the composition and function of the large intestine metabolic niche. The compositional characteristics of the gut microbiome are
influenced by a number of factors, with the initial seeding and trajectory toward an healthy adult-like diversity and stability determined by mode of
delivery (C-section vs. par vaginum) and early feeding patterns (breast feeding vs. formula feeding). Host genetics also plays a role as does geographical
location, whereas stress across the life span may be viewed as a threat to the diversity of the gut microbiome. A Westernized diet is also thought to
compromise the integrity of the gut microbiome, whereas increased fiber intake is associated with increased diversity. Exercise might also promote the
stability of a health microbiome, although the ageing process is associated with a narrowing diversity, as are many disease states and excessive/
inappropriate antibiotic use. A number of intrinsic factors, reviewed in details elsewhere by Simren et al. (2013) and partially depicted here, also
determine the composition of the gut microbiome, including gastric acid secretion, anticommensal sIgA and antimicrobial peptide production, and
gastrointestinal motility.
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metabolism was also well recognized for many drugs
such as oral contraceptives. However, it was rarely
considered to have a significant impact clinically except
in cases of interactions where broad-spectrum antibi-
otics resulted in transiently reduced bioavailability of
the drugs (Masters and Carr, 2009). In contrast, it is
really only as our knowledge of the increasing role that a
diverse microbiota can have on health, and the enor-
mous metabolic potential, that interest has turned
to the more direct effects of the gut microbiome on
metabolizing drugs.
A. Direct Microbial Metabolism of Xenobiotics
Direct microbial biotransformation of xenobiotics
occurs following their ingestion, and the nature of these
interactions depends on whether the compounds en-
countered by the gut microbiome are poorly absorbed or
are first conjugated by the liver and subsequently reach
the intestine via biliary excretion. Once present in the
intestinal lumen, an array of bacterial enzymes is
capable of a diverse set of chemical reactions. Glucuro-
nides are abundant in the gut and are subject to
processing by microbial b-glucuronidase enzymes,
which act to liberate glucuronic acid sugars from
conjugated compounds (Pellock and Redinbo, 2017). A
recent analysis of the Human Microbiome Project
gastrointestinal database is instructive on the complex-
ity of this metabolic function, revealing a total of 3013
microbiome-encoded b-glucuronidases, which clustered
into structural categories with differing functional
capacities for various glucuronide substrates (Pollet
et al., 2017). Although the extent of this variation is
somewhat bewildering, an earlier study neatly demon-
strated the important implications arising from these
observations in that the propensity for enzyme inhibi-
tion varied according to the bacterial provenance of the
orthologous enzymes (Wallace et al., 2015). Endogenous
glucuronides such as serotonin glucuronide as well as
glucuronidated catecholamines are processed in this
way (Asano et al., 2012; Hata et al., 2017). Exam-
ples of exogenous glucuronides subject to microbial
deconjugation include both therapeutic agents such as
the colorectal cancer drug irinotecan and the NSAID
diclofenac (Roberts et al., 2013), diet-derived carcino-
genic compounds such as 2-amino-3-methyl-3H-imidazo
[4,5f]quinoline (Humblot et al., 2007), and likely many
representatives from the broad polyphenol family of
compounds (Piwowarski et al., 2017; Williamson and
Clifford, 2017), including dietary flavonoids (Murota
et al., 2018).
In addition to the hydrolysis of these glucuronide
conjugates, there are also gut microbial polysaccha-
ride lysases, lipases, reductases (azoreductases and
nitroreducases), endoglycosidases, transferases, mono-
and dioxygenases, sulfatases, and glycyl radical en-
zymes (Claus et al., 2016; Koppel et al., 2017). As for
theb-glucuronidases, some of these enzyme families, such
as the glycyl radical enzymes and S-adenosylmethionine
enzymes, have multiple family members and likely
different substrate specificities and functions (Lehtio
andGoldman, 2004; Haft and Basu, 2011;Murphy et al.,
2011). This confers a spectrum of functional metabolic
properties on the gutmicrobiome ranging fromproteolysis
and deconjugation to amine formation and acetylation
(Tralau et al., 2015;Wilson andNicholson, 2017). Taken
together, this functional metabolic repertoire includes
the capacity for clinically relevant activation (e.g.,
sulfasalazine) (Peppercorn and Goldman, 1972b),
reactivation (e.g., irinotecan/SN-38) (Wallace et al.,
2010), and detoxification (e.g., digoxin) (Haiser et al.,
2013) of xenobiotics with broad implications for drug
action and toxicity (see Table 1). The administration of
probiotics such as Lactobacillus reuteri K8 and Lacto-
bacillus rhamnosus K9 in mice has also been shown to
alter the fecal activity of microbial enzymes such as
sulfatase, arylsulfatesulfotransferase,andb-glucuronidase,
with implications for the pharmacokinetics of acetamino-
phen in the case of the former (K8) probiotic (Kim et al.,
2018).
In many cases, as for dietary compounds such as the
artificial sweeteners xylitol and stevioside, the precise
enzymes carrying out their metabolism or their origin
microbial species are unknown (Koppel et al., 2017). For
others, the enzymatic pathways and the associated
implications are becoming clearer. A chalcone isomer-
ase has been isolated from Eubacterium ramulus, a
human fecal anaerobe capable of degrading various
flavonoids (Herles et al., 2004). Experimentally,
Western-style high-fat diets have been associated with
a diminished microbial capacity to metabolize flavo-
noids through bacterial chalcone synthase, and
microbiome-derived flavonoids can ameliorate the rate
of postdietingweight gain (Thaiss et al., 2016a; Chilloux
and Dumas, 2017). Daidzin and genistin, glycoside
isoflavones, are converted to daidzein and genistein by
bacterial b-glucosidases, with the important estrogen
equol being the end product following further biotrans-
formation of daidzein (Setchell et al., 2002). Human
gut bacteria Adlercreutzia equolifaciens and various
Slackia spp. (all related to Eggerthella lenta) have been
shown to produce these metabolites (Maruo et al.,
2008; Tsuji et al., 2010; Matthies et al., 2012), and the
daidzein-induced gene cluster has been described
(Tsuji et al., 2010).
B. Microbial Regulation of Host Hepatic
Drug Metabolism
The range of metabolic activity of the gut microbiome
outlined above is supplemented via microbial regula-
tion of host enzyme expression and activity in both the
liver and large intestine, effectively regulating aspects
of host drug absorption and metabolism (see Table 2).
The use of germ-free animals has revealed that impor-
tantmetabolic enzymes are either up- or downregulated
202 Clarke et al.
T
A
B
L
E
1
M
ic
ro
bi
al
en
zy
m
es
an
d
as
so
ci
at
ed
bi
ot
ra
ns
fo
rm
at
io
ns
M
ic
ro
bi
al
E
n
zy
m
e/
P
at
h
w
ay
S
u
bs
tr
at
e
C
la
ss
E
xa
m
pl
es
B
io
tr
an
sf
or
m
at
io
n
C
om
m
en
t
R
ef
er
en
ce
b
-G
lu
cu
ro
ni
da
se
P
h
ar
m
ac
eu
ti
ca
l
Ir
in
ot
ec
an
(c
ol
or
ec
ta
l
ca
nc
er
dr
ug
),
D
ic
lo
fe
na
c,
In
do
m
et
ha
ci
n
(N
S
A
ID
s)
G
lu
cu
ro
n
id
e
hy
dr
ol
ys
is
Ir
in
ot
ec
an
is
co
nv
er
te
d
to
S
N
-3
8-
G
by
th
e
h
os
t
an
d
co
n
ve
rt
ed
ba
ck
in
to
cy
to
to
xi
c
S
N
-3
8
in
in
te
st
in
e
w
it
h
as
so
ci
at
ed
ga
st
ro
in
te
st
in
al
si
de
ef
fe
ct
s;
ex
am
pl
e
of
en
te
ro
he
pa
ti
c
cy
cl
in
g
W
al
la
ce
et
al
.,
20
10
;
S
ai
tt
a
et
al
.,
20
14
E
n
do
ge
n
ou
s
S
er
ot
on
in
do
pa
m
in
e
A
sa
no
et
al
.,
20
12
;
H
at
a
et
al
.,
20
17
E
nv
ir
on
m
en
ta
l
po
ll
u
ta
nt
N
it
ro
to
lu
en
e
C
la
us
et
al
.,
20
16
D
ie
ta
ry
IQ
G
en
ot
ox
ic
/C
ar
ci
no
ge
ni
c
co
m
po
un
d
fo
rm
ed
in
m
ea
t
an
d
fi
sh
du
ri
ng
co
ok
in
g
H
u
m
bl
ot
et
al
.,
20
07
A
zo
re
du
ct
as
e
P
ha
rm
ac
eu
ti
ca
l
S
ul
fa
sa
la
zi
ne
(I
B
D
m
ed
ic
at
io
n)
A
zo
bo
nd
re
du
ct
io
n
S
ul
fa
sa
la
zi
ne
is
pr
od
ru
g
co
nv
er
te
d
to
th
e
ac
ti
ve
ag
en
t
5-
A
S
A
by
gu
t
m
ic
ro
be
s
P
ep
pe
rc
or
n
an
d
G
ol
dm
an
,
19
72
b
N
it
ro
re
du
ct
as
e
P
h
ar
m
ac
eu
ti
ca
l
B
ro
m
az
ep
am
,
C
lo
na
ze
pa
m
,
N
it
ra
ze
pa
m
(B
en
zo
di
az
ep
in
es
)
N
it
ro
re
du
ct
io
n
A
nt
ib
io
ti
c
pr
et
re
at
m
en
t
ca
n
ab
ol
is
h
en
zy
m
e
ac
ti
vi
ty
;
N
it
ra
ze
pa
m
is
m
et
ab
ol
iz
ed
in
to
7-
am
in
on
it
ra
ze
pa
m
,
w
hi
ch
un
de
rg
oe
s
ho
st
h
ep
at
ic
m
et
ab
ol
is
m
in
to
a
te
ra
to
ge
n
E
lm
er
an
d
R
em
m
el
,
19
84
;
F
uj
ii
et
al
.,
19
87
;
T
ak
en
o
an
d
S
ak
ai
,
19
91
C
ar
di
ac
gl
yc
os
id
e
re
du
ct
as
e
P
ha
rm
ac
eu
ti
ca
l
D
ig
ox
in
(C
ar
di
ov
as
cu
la
r)
R
ed
uc
ti
on
R
ea
ct
io
n
co
nt
in
ge
nt
on
th
e
co
rr
ec
t
st
ra
in
of
E
.l
en
tu
m
an
d
in
hi
bi
te
d
by
di
et
ar
y
ar
gi
ni
ne
H
ai
se
r
et
al
.,
20
13
T
ry
pt
op
h
an
as
e
D
ie
ta
ry
T
ry
pt
op
ha
n
D
ea
m
in
at
io
n
P
ro
du
ct
io
n
of
in
do
le
,
w
hi
ch
m
ay
ha
ve
a
ro
le
as
an
in
te
rs
pe
ci
es
an
d
in
te
rk
in
gd
om
si
gn
al
in
g
m
ol
ec
ul
e
L
ee
et
al
.,
20
15
G
ly
cy
l
ra
di
ca
l
en
zy
m
es
(c
h
ol
in
e
T
M
A
-l
ya
se
)
D
ie
ta
ry
C
ho
li
ne
C
-N
bo
nd
cl
ea
va
ge
el
im
in
at
io
n/
ox
id
at
io
n
P
ro
du
ct
io
n
of
T
M
A
,
as
so
ci
at
ed
w
it
h
at
he
ro
sc
le
ro
si
s
an
d
ca
rd
io
va
sc
ul
ar
di
se
as
e
fo
ll
ow
in
g
h
os
t
pr
od
u
ct
io
n
of
T
M
A
O
W
an
g
et
al
.,
20
11
;
K
oe
th
et
al
.,
20
13
;
C
ra
ci
un
et
al
.,
20
14
C
ar
n
it
in
e
ox
yg
en
as
e
(R
ie
sk
e-
ty
pe
ox
yg
en
as
e/
re
du
ct
as
e)
D
ie
ta
ry
C
ar
ni
ti
ne
O
xi
da
ti
on
/R
ed
uc
ti
on
P
ro
du
ct
io
n
of
T
M
A
,
as
so
ci
at
ed
w
it
h
at
he
ro
sc
le
ro
si
s
an
d
ca
rd
io
va
sc
ul
ar
di
se
as
e
fo
ll
ow
in
g
h
os
t
pr
od
u
ct
io
n
of
T
M
A
O
K
oe
th
et
al
.,
20
13
;
Zh
u
et
al
.,
20
14
S
ac
ch
ar
ol
yt
ic
pa
th
w
ay
s;
bu
ty
ry
l-
C
oA
:a
ce
ta
te
C
oA
tr
an
sf
er
as
e
D
ie
ta
ry
In
di
ge
st
ib
le
po
ly
sa
cc
ha
ri
de
s
F
er
m
en
ta
ti
on
P
ro
du
ct
io
n
of
sh
or
t
ch
ai
n
fa
tt
y
ac
id
s
M
or
ri
so
n
an
d
P
re
st
on
,
20
16
U
n
kn
ow
n
P
h
ar
m
ac
eu
ti
ca
l
L
ov
as
ta
ti
n
H
yd
ro
xy
la
ti
on
M
et
ab
ol
it
e
fo
rm
at
io
n
re
du
ce
d
fo
ll
ow
in
g
an
ti
bi
ot
ic
tr
ea
tm
en
t
Y
oo
et
al
.,
20
14
D
ec
ar
bo
xy
la
se
D
ie
ta
ry
L
-t
yr
os
in
e
R
em
ov
al
of
ca
rb
ox
yl
gr
ou
p
B
ac
te
ri
al
pr
od
uc
ti
on
of
p-
cr
es
ol
,
w
hi
ch
is
su
lf
at
ed
by
th
e
h
os
t.
P
-c
re
so
l
co
m
pe
te
s
w
it
h
ac
et
am
in
op
h
en
fo
r
su
lf
at
io
n
.
S
m
it
h
an
d
M
ac
fa
rl
an
e,
19
97
;
C
la
yt
on
et
al
.,
20
09
;
D
aw
so
n
et
al
.,
20
11
L
in
ol
ea
te
is
om
er
as
e
D
ie
ta
ry
L
in
ol
ei
c
ac
id
C
on
ju
ga
ti
on
P
ro
du
ct
io
n
of
co
nj
ug
at
ed
li
no
le
ic
ac
id
fr
om
fo
od
-d
er
iv
ed
la
ct
ob
ac
il
li
Y
an
g
et
al
.,
20
14
U
n
kn
ow
n
P
h
ar
m
ac
eu
ti
ca
l
L
-D
op
a
p-
D
eh
yd
ro
xu
la
ti
on
/
D
ec
ar
bo
xy
la
ti
on
L
-D
op
a
ca
n
al
so
bi
nd
to
H
.
py
lo
ri
;
fo
od
-a
ss
oc
ia
te
d
st
ra
in
of
L
.
br
ev
is
ex
pr
es
se
s
ty
ro
si
ne
de
ca
rb
ox
yl
as
e
B
er
gm
ar
k
et
al
.,
19
72
;
G
ol
di
n
et
al
.,
19
73
;
N
ie
h
u
es
an
d
H
en
se
l,
20
09
;
Z
h
an
g
an
d
N
i,
20
14
(c
on
ti
n
u
ed
)
Microbial Xenobiotic Metabolism 203
in the absence of a gut microbiome. This includes
glutathione transferases (detoxification enzymes),
gastrointestinal glutathione peroxidase (reduction of
lipid hydroperoxides), epoxide hydrolases (detoxifica-
tion of genotoxic compounds), N-acetyltransferases
(phase II conjugation reactions), and sulfotransferases
(detoxification and hormone regulation) (Meinl et al.,
2009). Both mRNA and protein expression of
CYP3a11 is markedly reduced in the livers of adult
germ-free mice (Selwyn et al., 2015b). CYP3a11 is the
mouse homolog of human CYP3A4, and this enzyme
metabolizes more than 60% of all drugs. Conversely,
the same study showed that gene expression levels
of Cyp1a2 (metabolic activation of procarcinogens
and deactivation of certain anticancer drugs) and
Cyp4a14 (metabolism of fatty acids and eicosanoids)
were both substantially increased in germ-free mice.
Studies also indicate that the impact of the gut
microbiota on hepatic drug-processing genes is
enzyme-specific and depends on both age and sex,
with expression patterns varying across the life span
according to developmental periods, and the most
marked effects observed inmalemice at 90 days of age
(Selwyn et al., 2015a).
Microbial colonization of germ-free animals nor-
malized the expression of Cyp3a and Cyp4a gene
clusters to those observed in conventional animals
(Selwyn et al., 2016). Administration of VSL3, a
probiotic formulation containing eight live strains of
bacteria, did not impact on the expression of these
genes in germ-free animals but did modulate their
expression in conventional animals, suggesting that
the composition of the host microbiota can influence
the effects of other microbes on expression of host
drug–metabolizing enzymes. Moreover, this inter-
vention confirms that less extreme microbiome ma-
nipulations, outside of proof-of-principle studies in
microbiota-deficient animals, can influence the ex-
pression of hepatic drug–processing genes during
adulthood. Colonization effects are likely strain specific
because monoassociation of germ-free mice with both
Lactobacillus plantarum Nizo2877 and Escherichia
coli Nissle 1917 decreased the expression of Cyp1a2
mRNA to conventional levels but did not act to restore
the decreased expression of Cyp3a11 mRNA. Differ-
ential effects for these strains were also noted with
increased expression of hepatic Cyp2e1 following
monoassociation with L. plantarum Nizo2877 but
decreased expression following colonization of E. coli
Nissle 1917 (Jourova et al., 2017).
This transcriptional regulation of such a range of
important host drug–processing genes by the gut
microbiome may have important implications in
terms of microbiome–drug interactions that are not
currently routinely considered. This is especially
salient in the context of antibiotic usage and the
transient depletion of important members of the
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bacterial consortium in the gut microbiota. It has
been shown, for example, that ciprofloxacin (a broad-
spectrum fluoroquinolone antibiotic) reduces hepatic
Cyp3a expression and metabolism of the benzodiaze-
pine triazolam (Toda et al., 2009a). This was associated
with a reduction in lithocholic acid–producing bacteria,
consistent with the suggestion that lithocholic acid influ-
ences hepatic CYP expression (Toda et al., 2009b). It
should be noted that ciprofloxacin is metabolized in the
liver and can directly inhibit CYP1A2, CYP2D6, and
CYP3A4 (Bolhuis et al., 2011).Whether poorly absorbed
antibiotics that avoid significant hepatic metabolism,
such as vancomycin and rifaximin, also indirectly mod-
ulate hepatic CYP gene expression via depletion of the
gut bacteria is currently unknown. An improved un-
derstanding of the consequences of indirect host–
microbiome drug interactions during these exposures,
which are associated with concurrent and relevant drug
use, consumption of dietary supplements, or environ-
mental toxins (which might also alter the gut micro-
biome), is urgently required and should be considered in
drug development, safety pharmacology, and pharma-
cokinetic profiling (Fig. 2).
IV. Factors Influencing the Rate and Extent of
Gut Microbiome Xenobiotic Metabolism
Xenobiotics can become a candidate substrate for direct
processing if they are poorly absorbed, appropriately
formulated, or indirectly reach the colonic lumen follow-
ing biliary excretion, which is also a route through which
i.v. administered drugs can become subject to chemical
transformation by gut microbes. In considering the
rate and extent to which drugs will be exposed to direct
microbiome metabolism, there are a myriad of additional
factors that need to be considered (Hall et al., 1999).
The majority of orally administered drugs are normally
absorbed in the upper small intestine, the prime ab-
sorptive region of the intestine, assuming that the drug
is highly soluble and highly permeable in this region.
However, many drugs display poor solubility, which can
lead to slow and incomplete absorption with the drug
being absorbed from distal regions of the small intestine
and/or the colon. Drugs with low permeability through
the intestinal membrane, or drugs that are subject
to efflux by apically bound efflux proteins (e.g.,
P glycoprotein), can prolong drug residence within the
intestine, with greater amounts of those drugs reaching
distal regions of the intestine (Hall et al., 1999). Finally,
it should also be recognized that although microbial
abundance is lower in the small intestine, this should
not lead to the implicit assumption that it will have a
limited impact on the drugs that are predominantly
absorbed in this region. On the contrary, in the case in
intestinal CYP enzymes, which are present in the
intestine, but expressed in vastly lower amounts than
the liver, intestinally mediated CYP metabolism can
still be the major site of drug metabolism (Hall et al.,
1999). For example, in the case of cyclosporine, it is
estimated that up to half of the drug is metabolized by
intestinal CYP enzymes (Benet and Cummins, 2001),
illustrating that relatively low amounts of enzymes in
the small intestine could still potentially have a signif-
icant impact for orally administered drugs. This needs
to be considered in the context that due to our reliance
of fecal microbiota assessments, comparatively little is
known about the microbiota of the less accessible small
intestine (El Aidy et al., 2015).
Oral delivery of advanced drug formulations designed
for extended release (e.g., sustained release tablets) is
on the increase, circumventing absorption profiles that
would usually limit exposure of many drugs to the
TABLE 2
Microbial regulation of host hepatic cytochrome P450 drug-processing enzymes
Host Enzyme Impact of Germ-free Status Comment Reference
Cyp3a (mice) Decreased mRNA and protein Upregulated following colonization, but VSL3 probiotic
cocktail was not able to normalize their expression;
VSL3 moderately decreased mRNAs of Cyp3a44 and
Cyp3a11 in conventional mice; similar to the human
CYP3A gene cluster
Selwyn et al., 2016
Decreased mRNA and protein Evidence of developmental regulation with largest
effects seen at 90 days
Selwyn et al., 2015a
Decreased mRNA Monoassociation with L. plantarum Nizo2877 or E. coli
Nissle 1917 had no effect on mRNA expression
Jourova et al., 2017
Cyp1a2 (mice) Increased mRNA Largest effects seen at 90 days Selwyn et al., 2015a
Increased mRNA Monoassociation with L. plantarum Nizo2877 or E. coli
Nissle 1917 decreased mRNA expression
Jourova et al., 2017
Cyp2c (mice) Increased mRNA Largest effects seen at 90 days in male animals only Selwyn et al., 2015a
Cyp2e1(mice) Increased mRNA Largest effects seen at 90 days Selwyn et al., 2015a
Increased mRNA Monoassociation with E. coli Nissle 1917 but not
L. plantarum Nizo2877 decreased mRNA expression
Cyp4a (mice) Increased mRNA and protein Downregulated following colonization, but VSL3
probiotic cocktail was not able to normalize their
expression; similar to the human CYP4A cluster
Selwyn et al., 2016
Increased mRNA Evidence of developmental regulation and sex-specific
effects with largest effects seen at 90 days in male
animals only; increased mRNA between neonatal and
adolescent ages
Selwyn et al., 2015a
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colonic gut microbiota (Sousa et al., 2008). This ap-
proach has become popular, particularly for the more
effective treatment of neuropsychiatric disorders, but,
in addition to extending the economic life cycle of drugs
(Andrade, 2015), these modified release formulations
also increase the scope for drug–microbiome interactions
(Enright et al., 2016), and this is a feature rarely ap-
praised for its contribution to bioavailability.
In contrast to the usual objective of host metabolism,
biochemical modification of exogenous compounds by
our gut microbes is not always geared toward elimina-
tion of these foreign compounds. Once a substrate is
available for microbial metabolism, there are a number
of considerations that may determine its fate and the
extent to which it undergoes biotransformation. Much
like the host, these can be considered in terms of in-
terindividual and intraindividual variables (Kramer and
Testa, 2008, 2009). Individual-specific genetic makeup of
the host genome explains some differences in drug me-
tabolism, and host-genetic influences on gut microbiome
composition (Goodrich et al., 2016; Rothschild et al.,
2018) are also likely to play a role in influencing the rate
and extent of microbial xenobiotic metabolism. Microbial
enzymes, such as b-glucuronidases, can differ in substrate
selectivity and activity depending on the bacteria from
which they arise (Pollet et al., 2017). Of note, interindivid-
ual differences in the abundance of a cytochrome-encoding
operon, responsible for the deactivation of the cardiac drug
digoxin, have recently been reported, and this operon was
specific to drug-metabolizing strains of E. lenta and was
inducible by the drug it metabolizes (Haiser et al., 2013).
Other examples of inducible bacterial enzymes include the
lac operon of E. coli, which contains genes involved in
lactose metabolism (Wilson et al., 2007) that is expressed
Fig. 2. Metabolic activity of the gut microbiome. There are both direct and indirect mechanisms through which the gut microbiome can influence
xenobiotic metabolism to modulate efficacy, absorption, and bioavailability. Direct mechanisms include activation (conversion of prodrugs into active
drugs) and deactivation (detoxification). Direct binding of xenobiotics to bacterial cells is also possible (e.g., precursor binding). Indirect mechanisms
include enterohepatic cycling, as microbial biotransformation of compounds conjugated in the liver releases the conjugated group, reactivating the
compound. The expression of host hepatic CYP genes involved in xenobiotic metabolism is also influenced by the gut microbiome. Microbial metabolites
and/or production of pathway intermediates are also important from a pharmacokinetic perspective, as is the impact of bacterial translocation on
immune responses in the context of therapeutic efficacy.
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only when lactose is present and glucose is absent. It is
currently unclear the extent to which this feature of
inducibility, or indeed repression, generalizes to other
microbial enzymes important for xenobiotic metabolism
or whether constitutive expression is the more common
guiding rule in the gastrointestinal tract.
Factors that are known to influence the composition
of the gut microbiome, such as age and geography,
also overlap with variable drug pharmacokinetics and
impact on the relative abundances of genes coding for
xenobiotic-metabolizing enzymes (Das et al., 2016;
Quigley, 2017). However, our knowledge of interindi-
vidual variation of the gut microbiome during health
and disease at the taxonomic level is more advanced
than our grasp of the functional implications, if any,
of these compositional differences. Although stud-
ies suggest that we share a stable set of core func-
tions despite these variable gut microbiota profiles
(Human Microbiome Project Consortium, 2012), ac-
tual metabolic activity of the gut microbiome may
diverge from its functional potential (Tanca et al.,
2017). Because the activity of the gut microbiota
may exhibit resilience despite fluctuating community
membership and structure (Song et al., 2015), it is
thus not yet clear how many of the variables associ-
ated with alterations in the composition and stability
of the gut microbiome, including diet (Shanahan
et al., 2017), leave their mark on the capacity for
xenobiotic metabolism. It is, however, notable that there
are examples of disease-associated gut microbiomes,
such as depression, that do result in altered behav-
ioral phenotypes and host physiologic characteris-
tics when transferred into animal models (Kelly
et al., 2016a). The microbiome-associated metabolite
phenylacetic acid has also been shown to influence
disease phenotype in nonalcoholic fatty liver disease,
contributing to hepatic lipid accumulation (Hoyles
et al., 2018a).
Host xenobiotic metabolism is influenced by circa-
dian rhythms (Ozturk et al., 2017), and this may also
be true of microbial enzymatic activity because gut
microbiota community structure and metabolic activ-
ity also feature biologic rhythms, regulated by diet and
time of feeding rather than environmental 24-hour
light–dark cycles (Voigt et al., 2016; Johnson et al.,
2017). Jet lag can disrupt this diurnal microbiota
biology, a feature driven by alterations in feeding
patterns (Thaiss et al., 2014). Diurnal microbial be-
havior in turn is thought to influence the programming
of the colonic and hepatic circadian transcriptome via
fluctuating microbial metabolites with implications,
for example, for the hepatic detoxification of acetamin-
ophen that was dependent on the timing of adminis-
tration (Thaiss et al., 2016b). This was linked to
variation in the number of mucosa-associated bacteria
in the mouse gut across the circadian period, which was
10 times higher during the dark phase than during
the light phase. Circadian rhythm disruption and
appetite fluctuations, including carbohydrate craving,
are prominent in stress-related psychiatric disorders
such as major depression (Otte et al., 2016), which is
also associated with gut microbiome alterations (Dinan
and Cryan, 2017) (Fig. 3).
Fig. 3. Factors influencing gut microbiome xenobiotic metabolism. There
are a number of considerations that may determine the rate and the
extent to which accessible substrates undergo microbial biotransforma-
tion. Although compositional differences may not necessarily equate to
functional alterations, individual-specific genetic makeup of the host
genome explains some differences in gut microbiome characteristics and
may affect metabolic outputs. For example, microbial enzymes, such as
b-glucuronidases, can differ in substrate selectivity and activity, depend-
ing on the bacteria from which they arise. Other factors known to
influence the composition of the gut microbiome, such as age, hormone
status, and sex, also overlap with variable drug pharmacokinetics and
impact on the relative abundances of genes coding for xenobiotic-
metabolizing enzymes. Host xenobiotic metabolism is also influenced by
circadian rhythms, and this may also be true of microbial enzymatic
activity because gut microbiota community structure and metabolic
activity also feature biologic rhythms. It is also not yet clear how many of
the variables associated with alterations in the composition and stability
of the gut microbiome, including diet and geography, leave their mark on
the capacity for xenobiotic metabolism. An extreme example of the
modifiable nature of the gut microbiome in the context of diet and
geography lies in the transfer of bacterial genes encoding porphyranases,
agarases, and associated proteins from marine red algae to bacteria
residing in the gastrointestinal tract of Japanese individuals as a
consequence of their seaweed consumption.
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V. The Evolution of Microbial Enzymes for
Xenobiotic Metabolism
Host–microbe interactions are frequently viewed from
an evolutionary perspective (Davenport et al., 2017).
This informs the hologenome theory of evolutionwith the
holobiont encompassing a network of biomolecules de-
rived from both the host plus its associated microbes
(Bordenstein and Theis, 2015). Both the host and the
microbiome have evolved an extensive metabolic capac-
ity to deal with exogenous molecules with the combined
scope impressive in its breadth. Moreover, host–microbe
interactions appear critical to both normal andperturbed
regulation of metabolic activity, although not all aspects
of these actions are mutually beneficial, and the ratio-
nale for either the host or the microbiome to have
this capability is not always immediately obvious
(Patterson and Turnbaugh, 2014). For example, it has
been noted that the most common biotransformations
carried out by the gut microbiome (hydrolysis and
reduction) often serve to undo the oxidative and con-
jugative chemistry and indeed the intended eliminative
purpose of host hepatic drug metabolism (Koppel et al.,
2017). As detailed in Table 1, this can have conse-
quences in terms of deactivating or activating drugs in
the case of digoxin (Haiser et al., 2013) and sulfasala-
zine (Peppercorn and Goldman, 1972b), respectively.
Toxic or adverse consequences can also ensue, as is
the case for irinotecan (Wallace et al., 2010) or the
production of trimethylamine (TMA) from dietary car-
nitine and choline (Wang et al., 2011; Koeth et al., 2013).
In many cases, as in the latter example, host–microbe
interactions drive the adverse metabolic consequences
with the host responsible for processing of the interme-
diate TMA to the cardiotoxic TMA-N-oxide (TMAO; see
section on VII. A. The Microbiome and Therapeutic
Mechanism of Action, Efficacy, and Adverse Effects). In
mice, however, TMA is also a chemosignal involved in
species-specific social communication, acting to attract
mice but repel rats (Li et al., 2013).
An overarching question relates to why either the
host or the associated microbiome would evolve en-
zymes to metabolize substances that they could not
expect to come in contact with on a consistent basis. Or,
in other words, has microbial biochemistry evolved to
counter the vast increase in xenobiotics they encounter
both in the body and in environment as consequence of
industrialization and the subsequent expansion of the
chemical universe? It has been proposed that the answer
lies in the functional redundancy of the enzymes, with a
broad substrate specificity being a common feature of
reactions catalyzed by both host and microbial enzyme
(Patterson and Turnbaugh, 2014). The reactions carried
out by the gutmicrobiome frequently result in the release
of small molecules or carbon sources that can be used for
microbial growth (Koppel et al., 2017). Exposure of the
host, in contrast, to a wide array of bacterial metabolites
via the hepatic portal circulation demanded the emer-
gence of enzymatic flexibility primarily in the liver.
The most expansive enzyme families, such as the
b-glucuronidases, for example, reflect the wide avail-
ability of host-derived glucuronide substrates in the
gastrointestinal tract. Indeed, these enzymes have an
important role in the enterohepatic cycling of endoge-
nous substances such as bile acids (Long et al., 2017).
Because much of this chemistry involves the modifica-
tion of common functional groups, it is perhaps not that
surprising that modern pharmaceuticals, dietary com-
ponents, and environmental pollutants (see Table 1)
have become suitable substrates for the expansive
range of metabolic functions noted in this review.
VI. Stress-Related Disorders and the
Gut Microbiome
Stress is known to impact onhost xenobioticmetabolism,
particularly via induction of hepatic drug–metabolizing
enzymes possiblymediated by glucocorticoids or noradren-
aline (Konstandi, 2013; Pantelidou et al., 2017). Gut
microbiome alterations are frequently reported in stress-
related disorders such as depression, anxiety, and irrita-
ble bowel syndrome (Rajilic-Stojanovic et al., 2015; Foster
et al., 2017). The impact of stress on the already
compromised ageing microbiome is currently under con-
sideration and aligns with studies on the impact of stress
on the ageing brain at a time of life when chronic stressors
are common and in the context of shifting worldwide
population demographics (Prenderville et al., 2015; Allen
et al., 2017). Understanding the implications of stress–
microbiome interactions, and their functional metabolic
consequences and the implications for drug action, is
surely now an important research objective (Fig. 4).
VII. The Gut Microbiome and Xenobiotics in
Health and Disease: a Reciprocal Relationship
Although research efforts are ongoing to more pre-
cisely define a healthy gut microbiome (Falony et al.,
2016; Zhernakova et al., 2016), one of the most fre-
quently reported findings across an array of disorders is
a narrowing of gut microbiome diversity often accom-
panied by more specific but less consistent composi-
tional alterations at various taxonomic levels. This
includes central nervous system disorders such as de-
pression (Kelly et al., 2016a) and schizophrenia
(Schwarz et al., 2018), metabolic disorders such as
obesity (Torres-Fuentes et al., 2017) and diabetes
mellitus (Sohail et al., 2017), cardiovascular disorders
(Ryan et al., 2015; Winek et al., 2016), inflammatory
disorders such as inflammatory bowel disease (IBD)
(Sheehan and Shanahan, 2017), rheumatoid arthritis
and multiple sclerosis (Forbes et al., 2016), and cancer
(Aviles-Jimenez et al., 2017). Many of the therapeutic
interventions for such disorders are subject to
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biotransformation by our gut microbiome (see Table 3),
and the functional implications of these gut microbiome
alterations are not currently clear for microbial xenobi-
otic metabolism. This gap in knowledge surrounding
how these disease-associated gut microbiome alter-
ations feed into variations in drug response and
toxicity is further compounded by the realization that
many of the interventions themselves may also change
the composition and function of the gut microbiome.
A. The Microbiome and Therapeutic Mechanism of
Action, Efficacy, and Adverse Effects
Perhaps the best example in the literature that ties
the compositional characteristics of the gut microbiome
to drug action explicitly via microbial metabolism
relates to digoxin, a cardiac glycoside used in the
management of cardiovascular disorders. Haiser et al.
(2013) elegantly demonstrated that digoxin inactivation
was significantly influenced by the presence or absence
of metabolizing E. lenta strains in the gut microbiota of
patients, a feature offered as an explanation for variable
digoxin metabolite levels. Digoxin can be used for the
treatment of heart failure and atrial fibrillation, com-
mon disorders in the elderly who are noted to have
reduced elimination of digoxin (Haiser et al., 2013).
Despite the important conceptual advance provided by
this study and the template offered for the design of
future studies in this area, it is also worth noting that
digoxin use is on the decline amid the emergence of
alternative therapies with preferable safety profiles
(Haynes et al., 2008; Eade et al., 2013). Other examples
of microbiota–drug interactions of relevance to cardio-
vascular pharmacology include the hydroxylation of
lovastatin, albeit less well-characterized in terms of
specific enzyme involvement, in an animal model
following coadministration of an antibiotic that resulted
in a more extreme depletion of the microbiota that is
known to be present in cardiovascular disorders (Yoo
et al., 2014).
Choline TMA-lyase, a glycyl radical enzyme, is also
widely distributed among gut bacteria and exhibits
selectivity for choline cleavage. Choline is an essential
nutrient found in a wide variety of foods, but excess
conversion to TMA can lead to artherosclerosis as a
consequence of further metabolism by host hepatic
processing to TMAO (Zeisel and da Costa, 2009; Wang
et al., 2011; Koeth et al., 2013; Craciun et al., 2014).
TMAO can be produced from dietary TMA viametabolic
retroconversion (Hoyles et al., 2018b) and is predicted to
be produced from betaine (Jameson et al., 2016). TMA is
also produced by carnitine oxygenase, a Rieske-type
protein, using carnitine found in redmeat as a substrate
(Zhu et al., 2014). Choline TMA-lyase may be more
vulnerable to compositional variations in the gut
microbiome, and a recent study indicated that it was
only present in 26% of individuals, while also noting
that further studies were required to characterize the
TMA-producing capacity of bacterial communities in
at-risk groups (Rath et al., 2017) and consequential
effects on cardiovascular health. Interestingly, although
red meat has been negatively implicated as a substrate
source, commentators have pointed out that fish and
other seafood presumed to be beneficial to health also
contain significant amounts of TMAprecursors aswell as
free TMAO (Landfald et al., 2017). As TMAO is excreted
into urine via the kidney, and circulating levels of TMAO
increase significantly in patients suffering from chronic
kidney disease, there is a line of thought suggesting
plasma TMAO concentrations may be a better marker of
impaired renal function associated with atherosclerosis
of the renal vasculature rather than a direct cause of
Fig. 4. Stress and the gut microbiome. The gut microbiome recruits the
gut–brain axis to signal to the central nervous system. Signaling pathways
include the vagus nerve, neuroendocrine and neuroimmune routes, as well
as the impact on tryptophan metabolism. Communication along this axis is
bidirectional. Although the host response to stress is coordinated by the
brain with the central nervous system responding to stressors by structural
remodelling of neural architecture (McEwen, 2017), the gut microbiome
appears to be equally vulnerable and plastic in its response to homeostatic
threats directed at either terminus of the gut–brain axis (Dinan and Cryan,
2017). Hypothalamic–pituitary–adrenal axis programming and responses
show a dependency on an intact gut microbiome (Clarke et al., 2014b).
Preclinical studies indicate that stress exposure across the life span can
impact on gut microbiome composition. This includes early-life prenatal
(Golubeva et al., 2015) or postnatal stressors (O’Mahony et al., 2009) as well
as stress experienced during adulthood (Bharwani et al., 2016; Burokas
et al., 2017; Galley et al., 2017).
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atherosclerosis in humans (Miller et al., 2014). There are
still open questions as to what exactly constitutes a toxic
level of TMAO, as even in the absence of dietary sources
of methylamines, baseline levels of TMA and TMAO are
found in the circulation (De La Huerga et al., 1953;
Hoyles et al., 2018b). It is important to acknowledge that
circulating TMAOmay play a role in the protection from
hyperammonemia (Kloiber et al., 1988) and from glu-
tamate neurotoxicity (Minana et al., 1996). Chronic
exposure of mice to TMAO attenuates diet-associated
glucose tolerance, reducing endoplasmic stress and
adipogenesis in adipocytes (Dumas et al., 2017). Flavin
monooxygenase 3, associated with the conversion of
TMAtoTMAO, is downregulated by testosterone (Bennett
et al., 2013), suggesting possible differential processing of
TMA in men and women.
In the context of inflammatory disease, the microbiota
is responsible for the conversion of the prodrug
sulfasalazine into 5-aminosalicylate (5-ASA), the active
agent with anti-inflammatory properties used in the
treatment of IBD (Peppercorn and Goldman, 1972b).
This is a reaction carried out bymicrobial azoreductases,
enzymes noted to be present in a wide variety of anaer-
obic bacteria from the human microbiota (Chung et al.,
1992), making it difficult to envisage a loss of this
function being associated with the gut microbiome
alterations noted in IBD and resonating with the
concept of functional resilience mentioned earlier. It is,
however, notable that 5-ASA can be converted to
N-acetyl 5-ASA by intestinal bacteria, a reaction that
does show variability in human fecal samples (van
Hogezand et al., 1992). The metabolism of azo dyes to
aromatic amines is also carried out by azoreductases,
and fibers, antibiotics, or supplementation with live
cultures of lactobacilli were able to affect azoreductase
enzyme activity (Chung et al., 1992), an interesting
observation in light of their potential application in IBD.
Drugs used in the treatment of cancer also represent
examples of microbially-processed therapies and may
be associated with adverse and toxic side effects, as is
the case with irinotecan (Wallace et al., 2010). This
reaction involves b-glucuronidases, bacterial enzymes
noted to have a wide distribution in the gut microbiome
(Cole et al., 1985). It has also been demonstrated more
generally that of a panel of 30 chemotherapeutic drugs
examined in vitro against various bacteria, 10 were
found to be inhibited and six exhibited improved efficacy
in a way that could be linked to modification of the
chemical structure of the drug in the case of gemcitabine,
fludarabine, cladribine, and CB1954 (Lehouritis et al.,
2015).
Drug–drug interactions can also arise as a conse-
quence of microbial biotransformations. The hydrolysis
of the antiviral drug sorivudine to bromovinyluracil,
which is then subsequently metabolized by the host to
an inhibitor of host dihydropyrimidine dehydrogenase,
may lead to toxicity due to inhibited degradation and
increased concentrations of coadministered 5-fluorouracil
(5-FU) (Nakayama et al., 1997). Specifically, conversion
of bromovinyluracil by host dihydropyrimidine dehy-
drogenase produces a reactive intermediate that irre-
versibly inhibits the enzyme (Nishiyama et al., 2000).
The production of bromovinyluracil is carried out by
bacterial phosphorolytic enzymes with high enzymatic
activity observed in Bacteroides species (Alexander
et al., 2017).
More recently it has beendemonstrated that thewidely
present bacterial uracil phosphoribosyltransferase
(Martinussen and Hammer, 1994) can convert 5-FU to
the RNA-damaging 5-fluorouridine monophosphate us-
ing the nematode Caenorhabditis elegans as a model
system (Garcia-Gonzalez et al., 2017; Scott et al., 2017).
Also using thismodel, it has been demonstrated that the
deglycosylation of doxorubicin by Raoultella planticola
is associated with reduced toxicity (Yan et al., 2018).
Other gut-microbiota–mediated mechanisms through
which the pharmacological effects of chemotherapeu-
tics and immune therapeutics can be modulated include
translocation and immunomodulation following inter-
ventions such as cyclophosphamide, doxorubicin, and
TABLE 3
Clinical specialties, therapeutic interventions, and pharmacomicrobiomics
Specialty Drug Class Example Reference
Oncology Immune checkpoint inhibitor Anti-programmed cell death 1 protein Gopalakrishnan et al., 2018;
Routy et al., 2018
Anti–CTLA-4 antibodies Alexander et al., 2017
Antineoplastic enzyme inhibitor Irinotecan Wallace et al., 2010
Anthracycline Doxorubicin Yan et al., 2017
Alkylating agent Cyclophosphamide Alexander et al., 2017
Cardiology Statin Lovastatin Yoo et al., 2014
Cardiac glycoside Digoxin Haiser et al., 2013
Diabetes Biguanide Metformin Wu et al., 2017
Gastroenterology Sulfa drug Sulfasalazine Peppercorn and Goldman,
1972b
Psychiatry Antipsychotic Olanzapine Davey et al., 2012
Risperidone Bahr et al., 2015
Benzodiazepine Bromazepam Fujii et al., 1987
Clonazepam Elmer and Remmel, 1984
Nitrazepam Takeno and Sakai, 1991
Neurology Precursor L-Dopa Bergmark et al., 1972
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anti–CLTA-4 therapies (Alexander et al., 2017). Under-
standing how alterations in gut microbiota profiles can
dictate the host response to chemotherapeutic drugsmay
have important implications in clinical practice. Indeed,
recent studies confirm the potential importance of pa-
tient stratification on the basis of gut microbiome
composition to identify responders and nonresponders
to immunotherapy for the treatment of epithelial
tumors and melanomas (Gopalakrishnan et al., 2018;
Jobin, 2018; Routy et al., 2018) (Fig. 5).
B. Impact of Current and Putative Therapeutic
Interventions on Microbial Community Structure
and Function
Many xenobiotics also impact on the composition of
the gut microbiome, often in a clinically meaningful
way. The possible extent of these occurrences was
revealed recently following a screen of the interactions
between over 1000 marketed and individual gut bacte-
ria (Maier et al., 2018). The authors reported that 24% of
the drugs with human targets across therapeutic
classes inhibited the growth of at least one bacterial
strain in vitro. Commonly used drugs, such as antipsy-
chotics, proton-pump inhibitors (PPIs), hormones, and
anticancer drugs, were included in the screen. Although
the study largely focused on the in vitro antibac-
terial activity of each drug screened against one
representative bacterial strain per species, the implica-
tions formore complex bacterial communities need to be
considered. The results are also consistent with report-
ed interactions between these drugs (antipsychotics,
PPIs, and anticancer drugs) and the gut microbiome
documented in previous preclinical and clinical stud-
ies (Davey et al., 2012, 2013; Imhann et al., 2016;
Gopalakrishnan et al., 2018).
Exposure in incubation experiments to a panel of host-
targeted drugs, including digoxin and sulfasalazine,
induces subtle changes in community structure, but
more marked changes in the genes expressed by the
gut microbiome, including those genes involved in
xenobiotic metabolism (Maurice et al., 2013). Med-
ication use was also confirmed to be an important
Fig. 5. Examples of clinically relevant microbial biotransformations. Direct microbial biotransformation of xenobiotics occurs following their ingestion,
and, once present in the intestinal lumen, an array of bacterial enzymes is capable of modifying a diverse set of chemical structures, including
dietary and pharmaceutical compounds. Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation
(e.g., sulfasalazine) or inactivation (digoxin). Microbiota–drug interactions of relevance to cardiovascular pharmacology potentially include the
hydroxylation of lovastatin. Drug–drug interactions can also arise as a consequence of microbial biotransformations, such as the hydrolysis of the
antiviral drug sorivudine to bromovinyluracil. Bacterial conversion of dietary choline to TMA can lead to artherosclerosis as a consequence of further
metabolism by host hepatic processing to TMAO. The consequences of microbial metabolism are thus of broad importance for disease risk, and drug
efficacy and toxicity.
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covariate associated with human microbiota composi-
tional variation in a recent large-scale study of Belgian
and Dutch populations (Falony et al., 2016). A number
of studies focused on specific candidates have also
shone a light on this important area, as discussed
below.
Metformin, used for the treatment of type 2 diabetes,
has recently been shown to alter the gut microbiota
composition of treatment-naive individuals in a way
that improves glucose tolerance. This effect was prob-
ably achieved by promoting functional shifts in the gut
microbiome with, for example, the enrichment of genes
for carbohydrate metabolism, amino acid metabolism,
and lipopolysaccharide biosynthesis (Wu et al., 2017).
Metformin appears to have a dose-dependent antimi-
crobial effect with inhibition of specific bacterial strains
only apparent once tested at physiologic intestinal
concentrations (Maier et al., 2018). Interestingly, met-
formin can also promote in vivo the growth of specific
bacterial species such as Akkermansia muciniphila and
Clostridium cocleatum (Lee and Ko, 2014). This of
course makes it difficult to distinguish type 2 diabetes
versus metformin treatment signatures when assessing
human gut microbiota composition (Forslund et al.,
2015). Irinotecan can also alter the composition of the
intestinal microbiome in rats, although it is unclear how
well this aligns with the toxicity of this treatment (Lin
et al., 2012; Alexander et al., 2017).
Methotrexate results in reduced microbiota diversity
and compositional shifts in the abundance of Bacteroides
associated with the induction of diarrhea in rats (Fijlstra
et al., 2015). A recent systematic review indicates that
other prescription medications are also associated with
alterations in gut microbiome diversity, including PPIs,
opioids, and NSAIDs (Le Bastard et al., 2018). The effect
of PPIs in particular on gutmicrobiota diversity has been
noted to be characteristic of an unhealthy gut micro-
biome and may increase the risk for enteric infections
(Imhann et al., 2016).
There is mounting interest in the possibility that
psychotropic agents might alter the composition of the
gut microbiome (Kelly et al., 2016b). Currently, this has
best been explored for the atypical antipsychotic drug
olanzapine, which induces alterations in gut microbiome
composition in rodents linked to the weight gain and
other metabolic side effects that are associated with its
use (Davey et al., 2012, 2013;Morgan et al., 2014). It has
also been demonstrated that olanzapine has antimicro-
bial properties in vitro against two bacterial strains
commonly residing in the human gut (Morgan et al.,
2014). It is of note that olanzapine is metabolized by
hepatic glucuronidation, and an unusually high per-
centage (30%) of an oral dose is recoverable in human
feces (Kassahun et al., 1997). Prebiotic administration
concurrentlywith olanzapine can reduce the antipsychotic-
induced weight gain in rodents (Kao et al., 2018). Another
antipsychotic, risperidone, also causes shifts in gut
microbiome composition in mice (Bahra et al., 2015),
and in children and adolescents (Bahr et al., 2015).
More recently, it has been demonstrated that similar
bacterial species are affected by different and chemi-
cally diverse antipsychotics (Maier et al., 2018). Chronic
alcohol abuse also alters gut microbiome composition
(Leclercq et al., 2017), and other drugs of abuse possibly
do the same, such as methamphetamine (Ning et al.,
2017). More generally, substance use disorders are
associated with reduced microbiota diversity (Xu et al.,
2017).
Although the therapeutic potential of microRNAs
(miRNAs) is far from fully realized, these small nucle-
otide sequences with the ability to regulate gene
expression represent molecular effectors of importance
in a range of areas, including psychiatric disorders such
as depression and anxiety (Scott et al., 2015; Gururajan
et al., 2016; O’Connor et al., 2016) as well as cancer
(Slaby et al., 2017) and cardiovascular disorders (Mellis
and Caporali, 2018). Understanding the role of the gut
microbiome–miRNA interactions is a novel departure
that has seen evidence emerge from studies in germ-free
rodents of microbial regulation of miRNA expression in
brain regions of importance for neuropsychiatry such
as the amygdala, prefrontal cortex, and hippocampus
(Chen et al., 2017; Hoban et al., 2017; Moloney et al.,
2017). It also seems that host miRNA production by
intestinal epithelial cells has a role in shaping the gut
microbiome by affecting bacterial growth (Liu et al.,
2016), and fluctuations in microbial composition of the
gut microbiome are associated with alterations in fecal
miRNAs (Moloney et al., 2018). This will be an impor-
tant consideration if the miRNA-targeted therapeutics
in clinical development make their way to the clinic for
the treatment of disorders associatedwith gutmicrobiome
alterations.
Dietary compounds exert a major impact on the gut
microbiome. In mice, a number of nutritional and
nutraceutical interventions for cardiovascular disease
were compared against a standard pharmaceutical
intervention for their impact on the gut microbiome.
Plant sterol ester produced the strongest compositional
effect with more modest alterations noted following oat
b-glucan and bile salt hydrolase-active L. reuteri APC
2587, with few effects noted for atorvastatin. Functional
alterations following plant sterol ester, oat b-glucan,
and atorvastatin were also noted in this study, using
microbial and host-derived metabolites in the serum
metabolome as a readout (Ryan et al., 2017). Polyun-
saturated fatty acids (PUFAs) are thought to exert
an antidepressant effect, possible via their anti-
inflammatory properties (Burhani and Rasenick, 2017).
Omega-3 PUFAs also have important cardioprotective
and neurodevelopmental properties and support the
function and aging of the central nervous system
(Pusceddu et al., 2016). Dietary omega-3 PUFA status
impacts on the cecal microbiome and metabolome in
212 Clarke et al.
mice (Robertson et al., 2017b) and is also able to impact
on gut microbiota development in adolescence and
adulthood when varied in the maternal and early-
postnatal diet (Robertson et al., 2017a). It has also been
reported that the disruptions to the gut microbiota
induced by the early-life stressor maternal separation
in female rats can be rescued by omega-3 PUFA supple-
mentation (Pusceddu et al., 2015). In clinical populations,
and although omega-3 PUFA supplementation did not
change gut microbiome diversity or composition at the
phyla level, an increase in several short chain fatty acid–
producing bacteria such as Bifidobacterium, Roseburia,
and Lactobacillus was noted (Watson et al., 2017).
Dietary phytochemicals can induce gut microbiota
alterations, exerting prebiotic-like effects to stimulate
the growth of beneficial bacteria (Laparra and Sanz,
2010). Recent revisions of the definition of prebiotics
have expanded their scope and now include both PUFAs
and phytochemicals (Gibson et al., 2017). Polyphenolic
phytochemicals in particular are known to exert bene-
ficial health effects beyond their antioxidant capacity
(Stevenson and Hurst, 2007). Recent evidence suggests
that resveratrol, for example, may act to remodel the
gut microbiome to yield cardiovascular benefits, anti-
obesity effects, and improvements in glucose homeosta-
sis (Chen et al., 2016; Bird et al., 2017; Sung et al.,
2017). Flavonoids also shape gut microbiota member-
ship and function (Oteiza et al., 2018). Other dietary
compounds known to alter the composition of the gut
microbiome include noncaloric artificial sweeteners
such as saccharin, sucralose, and aspartame (Suez
et al., 2015), a feature with functional implications
associated with the induction of glucose intolerance
in mice (Suez et al., 2014). Although probiotics are
not thought to substantially change the global com-
positional characteristics of the gut microbiome
(Kristensen et al., 2016), they do impact on functional
metabolic outputs such as the production of short chain
fatty acids and other pharmabiotics, which may be
important in their propensity to influence host health
(Patterson et al., 2014).
C. Environmental and Industrial Chemicals
The capacity of the gut microbiome to metabolize
environmental chemicals is mediated by enzymes with
awidedistribution suchasb-glucoronidases, azoreductases,
and nitroreductases, which are able to chemically
transform a range of agents such as nitrotoluenes,
pesticides, polychlorobiphenyls, azo dyes, and metals
(Claus et al., 2016).Many of these same chemical agents
can also alter the composition and/or function of the gut
microbiota. Chronic exposure to low doses of the insec-
ticide, Chlorpyrifos, changed the composition of
the gutmicrobiota in both a simulated human intestinal
microbiota preparation and rats, reducing the abun-
dance of Lactobacillus spp. and Bifidobacterium spp,
bacteria presumed to be beneficial (Joly et al., 2013).
Glyphosate, the most commonly used herbicide
(Cuhra et al., 2016), inhibits microbial enzymes (5-
enolpyruvylshikimate-3-phosphate synthase), and some
glyphosate formulations do have antibacterial properties
(Tarazona et al., 2017). It remains to be seenwhether the
detrimental impact of glyphosate seen on soil, plant, and
farm animal microbiomes will be consistently reflected
in the human microbiome where the concentrations
reached are usually much lower (Flandroy et al., 2018).
Heavy metals such as mercury, lead, cadmium, and
arsenic may also have an important impact on the gut
microbiota (Lu et al., 2015). Traffic-related air pollu-
tion can result in a decreased relative abundance of
Bacteroidaceae and an increased relative abundance of
Coriobacteriaceae (Alderete et al., 2018). Exposure to
endocrine-disrupting chemicals such as bisphenol A and
ethinyl estradiol, by incorporation into the diet from
periconception through weaning, induced generational
and sex-dependent gut microbiome changes in mice,
including increased relative abundances of Bacteroides,
Prevotellaceae, and Akkermansia (Javurek et al., 2016).
The collective literature in this area requires further
elaboration to understand the implications for host
health, not least within a framework that places the
characteristics of the early-life microbiome as critical to
the subsequent emergence of adult pathologies (Clarke
et al., 2014a; Claus et al., 2016) (Fig. 6).
VIII. Experimental Approaches
in Pharmacomicrobiomics
Understanding the complex and bidirectional inter-
play between the gut microbiome and xenobiotics
requires an array of experimental approaches geared
toward extracting the necessary complementary infor-
mation. Many of the strategies employed, such as the
use of microbiota-deficient animals, are commonly
applied across cognate areas of microbiome research
(Williams, 2014; Luczynski et al., 2016). This includes
both germ-free models or those generated via deple-
tion of the gut microbiota with a cocktail of antibiotics,
and can provide valuable pharmacokinetic and phar-
macodynamic insights. These approaches are not
without their limitations, not least because of the
intrinsic gastrointestinal and microbial differences
between humans and rodents (Nguyen et al., 2015).
There are also physiologic and morphologic differ-
ences between germ-free animals and conventional
controls relevant for xenobiotic metabolism (Sousa
et al., 2008). For example, host hepatic enzyme
expression and activity are altered in animals reared
in a germ-free environment (Selwyn et al., 2016).
However, the use of these animal models in mono-
association studies or following the transplant of
human microbiota profiles is clearly an invaluable
option (Haiser et al., 2014). Insights from inverte-
brate models, such as the nematode C. elegans, are
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increasingly used to inform our understanding of
host–microbe interactions (Clark and Walker, 2018),
and in the current context, a number of examples have
been discussed, including studies focused on the
chemotherapeutics doxorubicin (Yan et al., 2018) and
5-FU (Garcia-Gonzalez et al., 2017; Scott et al., 2017).
Conceptually, contrasting lower gut metabolites with
upper gut metabolites in rodents or comparing extended
Fig. 6. Xenobiotics that alter the gut microbiome. Many xenobiotics also impact on gut microbiome characteristics. This includes pharmaceutical
compounds such as metformin and methotrexate and psychotropic agents such as olanzapine. Other prescription medications are associated with
alterations in gut microbiome diversity, including PPIs, opioids, and NSAIDs. Dietary compounds also exert a major impact on the gut microbiome,
including polyphenolic phytochemicals (resveratrol, flavonoids), polyunsaturated fatty acids, and plant sterol ester. In addition, environmental and
industrial chemicals, including endocrine disrupting chemicals, heavy metals, pesticides, and pollutants, exert an influence on gut microbiome
structure, composition, and function.
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release versus immediate release formulations or i.v.
drug delivery with oral drug delivery in human in vivo
studies can also be informative (Sousa et al., 2008). More
routine screening of reciprocal microbiome–xenobiotic
interactions can be conducted in various in vitro batch
culture or fermentation systems or in the more complex
simulator of the human intestinal microbial ecosystem,
as was demonstrated for the insecticide Chlorpyrifos
(Sousa et al., 2008; Joly et al., 2013; Ou et al., 2015).
Large scale in vitro screening of commonly used drugs for
antibacterial activity also offers important information
(Maier et al., 2018). There are also advantages to the use
of in silico models to predict outcome from a variety of
inputs, possibly by combining microbiota metabolism
rates with host drug absorption and metabolic rates.
Specifically adapting many of the emerging physiologi-
cally based pharmacokinetic models, which predict drug
levels in tissues based on a variety of drug and host
parameters (Min and Bae, 2017; Thiele et al., 2017;
Donovan et al., 2018), to allow for greater contribution
of microbiota-mediated metabolism, may be a useful
approach to predict overall clinical impact.
Fecal sample incubations are often used in xenobiotic
metabolism studies, as they are easily accessible and
provide a reasonably reliable means of assessing the
metabolic activity of the colonic microbiota. Fecalase or
cecalase, stable and translationally relevant cell-free
extracts of feces or cecal matter with bacterial enzymatic
activity, are frequently used incubations (Tamura et al.,
1980). This has been applied in the study of lovastatin
(Yoo et al., 2014) and amlodipine (Yoo et al., 2016) and to
look at the effect of probiotics on the pharmacokinetics
of acetaminophen (Kim et al., 2018). Concerns about the
variability of the assay have seen the development of a
fecal microbial enzyme mix (Yeo et al., 2012).
Haiser et al. (2014) have outlined how these ap-
proaches might be combined in a framework for studying
microbial drug metabolism that includes functional
metagenomics to gain mechanistic insights and bioinfor-
matics to guide rationalmicrobiome-targeted therapeutic
interventions. The value of such an approach once it leads
to well-defined enzyme biochemistry can be seen in an
earlier study that demonstrated that it was possible to
selectively inhibit bacterial b-glucuronidases to alleviate
drug-induced gastrointestinal toxicity arising from irino-
tecan (Wallace et al., 2010). There is also a variety of
predictive and computational tools for the evaluation of
microbial effects on drugs during gastrointestinal pas-
sage that can be used to streamline the process and
provide targets for downstream in vitro and in vivo
hypothesis assessments (Pieper and Bertau, 2010; Klu-
nemann et al., 2014; Magnúsdóttir and Thiele, 2018).
Many of the in vitro approaches discussed are perhaps
overly simplistic and do not best capitalize on the unique
features of the gut ecosystem, such as microniches, pH
gradients, and dynamic microbe–tissue interactions
(TralauandLuch, 2013).Organ-on-a-chipmicrophysiological
systems are likely to increase efficiency and contribute
in the future to a better understanding of microbial
metabolism and host–microbiome crosstalk (Park et al.,
2017). Gastrointestinal organoids can be used to more
accurately model aspects of epithelial barrier dynamics,
including cellular differentiation and proliferation, in
specific intestinal segments bring advantages over cell
culture models in unraveling the molecular basis of the
host–microbe interactions (Hill and Spence, 2016).
Meanwhile, recent reports of an ingestible electronic
capsule that can provide real-time information on
gastrointestinal oxygen, hydrogen, and carbon dioxide
may ultimately see use as a chemical biosensor to
improve our understanding of the biogeography of gut
microbial metabolism (Kalantar-Zadeh et al., 2018).
Indeed, this is already partially functional in this
regard because the detection of hydrogen signals can
be used as a proxy for regional fermentation patterns
(Fig. 7).
IX. Toward Microbiome-Based Treatments and
Novel Biotherapeutics
The prospect of targeting the microbiome for enhancing
drug efficacy and therapeutic benefit is appealing, and the
development of innovative, more personalized approaches
in the practice of medicine can potentially be expedited
with successful incorporation of our knowledge of host–
microbe interactions outlined above. A number of other
options are also currently under consideration and include
drug delivery via designer probiotics or biotherapeutics
that take advantage of the modified biochemical prowess
of gut bacteria (Maxmen, 2017). For example, a genetically
engineered Lactococcus lactis–secreting interleukin-10
has been used to deliver a localized therapeutic dose of
IL-10 for the amelioration of murine colitis in an animal
model of IBD (Steidler et al., 2000). The use of de-
signer lactic acid bacteria as factories for the production
of antimicrobial and anti-inflammatory biomolecules may
also see utility in the future treatment of infectious
diseases, cancer, and metabolic diseases (Cano-Garrido
et al., 2015; Singh et al., 2017). Meanwhile, next-
generation probiotics may be based on the use of microbes
found to bedeficient in certain disorders, as is the case ofA.
muciniphila in obesity, diabetes, and cardiometabolic
diseases (Cani and de Vos, 2017), or Faecalibacterium
prausnitzii in IBD if the positive preclinical results in
models of colitis successfully translate to the clinic (O’Toole
et al., 2017). Pathogen-specific antimicrobials and the
development of bacteriocins as alternative therapeutic
options is another avenue under exploration (Maxson
and Mitchell, 2016; Mathur et al., 2017; Munguia and
Nizet, 2017), as is thepotential use of bacteriophage (Forde
andHill, 2017). Precision editing of the gutmicrobiotamay
also be possible, with an example being the use of
tungstate treatment to selectively inhibit microbial re-
spiratory pathways, which are operational specifically
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during episodes of localized gut inflammation (Zhu et al.,
2018). It remains to be seen whether fecal microbiota
transplantation, which has been so effective in the treat-
ment of recurrent Clostridium difficile infection, will also
see applications in this area (de Groot et al., 2017).
A. Psychobiotics
Psychobiotics were originally defined as “a live
organism that, when ingested in adequate amounts,
produces a health benefit in patients suffering from
psychiatric illness” (Dinan et al., 2013). That has since
expanded to include prebiotics that enhance the growth
of beneficial gut bacteria and also to include healthy
individuals (Sarkar et al., 2016). Currently, preclinical
behavioral screening platforms are most frequently
used to identify candidate psychobiotics for further
evaluation in clinical platforms (Bravo et al., 2011;
Savignac et al., 2014, 2015; Burokas et al., 2017). This
Fig. 7. Experimental approaches. Although we have been aware of isolated, but clinically relevant examples for a number of years, most commentators
agree that the current bank of known pharmacomicrobiomic reactions is likely to be expanded greatly in future years. Coupled with clinical
observations, a range of experimental approaches may be geared toward extracting complementary information about the complex and bidirectional
interplay between the gut microbiome and xenobiotics. Many of the strategies employed, such as the use of germ-free models or those generated via
depletion of the gut microbiota with a cocktail of antibiotics, can provide valuable pharmacokinetic and pharmacodynamic insights. Insights from
invertebrate germ-free models, such as the nematode C. elegans, are increasingly used to inform our understanding of host–microbe interactions. More
routine screening of reciprocal microbiome–xenobiotic interactions can be conducted in various in vitro batch culture or fermentation systems or in the
more complex simulator of the human intestinal microbial ecosystem. Fecal sample incubations, such as fecalase or cecalase assays, are often used in
xenobiotic metabolism studies. Functional metagenomics and bioinformatics can be used to guide rational, mechanistically-oriented microbiome-
targeted therapeutic interventions. There is also a variety of predictive and computational tools for the evaluation of microbial effects on drugs during
gastrointestinal passage that can be used to streamline the process and provide targets for downstream in vitro and in vivo hypothesis assessments.
Organ-on-a-chip microphysiological systems are likely to increase efficiency and contribute in the future to a better understanding of microbial
metabolism and host–microbiome crosstalk. Gastrointestinal organoids can be used to more accurately model aspects of epithelial barrier dynamics,
including cellular differentiation and proliferation, in specific intestinal segments and bring advantages over cell culture models in unraveling the
molecular basis of the host–microbe interactions.
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has met with somewhat mixed results in healthy human
subjects with strain-specific positive results (Allen
et al., 2016; Papalini et al., 2018) and a failure to
translate (Kelly et al., 2017).Refinements of the discovery
pipelinemay be necessary at various pressure points, and
this could include the development of psychobiotics with
specific mechanisms of action, tailored toward individual
patient requirements (Bambury et al., 2018).
One option in this regard may be the selection of
psychobiotics to fine-tune host or microbial tryptophan
metabolism, an important source of neuroactives for
microbiome–gut–brain axis signaling, including thera-
peutic targets for stress-related disorders such as sero-
tonin and kynurenine (O’Mahony et al., 2015; Yano et al.,
2015; Kennedy et al., 2017). Candidate psychobiotics
that beneficially impact on host tryptophan metabolites
include Bifidobacterium longum subsp. longum 35624
(previously B. infantis 35624) (Desbonnet et al., 2008)
and L. reuteri (Marin et al., 2017). Bacterial metabolism
of tryptophan to indole compounds may be equally
important because either in their own right or following
host processing, these microbial tryptophan metabo-
lites can impact on host physiology and behavior (Lee
et al., 2015). Next-generation psychobiotics may be
selected to metabolize tryptophan at specific gut
locations, as is the case for specific mucin utilizing
Peptostreptococcus species, which produce indoleacrylic
acid close to the intestinal epithelium, where it acts
Fig. 8. Microbial contribution to drug metabolism. Following enteral administration, the physiochemical properties or formulation of a drug impacts
the region of the gastrointestinal tract where the major exposure to microbial drug metabolism occurs. The nature of these interactions depends on
whether the compounds encountered by the gut microbiome are poorly absorbed or are first conjugated by the liver and subsequently reach the
intestine via biliary excretion, which is also a route through which i.v. administered drugs can become subject to chemical transformation by gut
microbes. The majority of orally administered drugs are normally absorbed in the upper small intestine assuming that the drug is highly soluble and
highly permeable in this region. Although there is a lower density of microbes in the small intestine, we have an incomplete understanding of the
impact of microbial activity in different regions of the gastrointestinal tract, and there may be important implications of region-specific microbial drug
metabolism for health and disease. However, many drugs display poor solubility, which can lead to slow and incomplete absorption with the drug being
absorbed from distal regions of the small intestine and/or the colon. Drugs with low permeability through the intestinal membrane can lead to greater
amounts of those drugs reaching these distal regions of the intestine. Drugs can also become a candidate substrate for direct microbial processing if
they are appropriately formulated. The highest density of bacteria is found in the colon, and the prevalent use of advanced drug formulations designed
for extended release (e.g., sustained release tablets) is on the increase, circumventing absorption profiles that would usually limit exposure of many
drugs to the colonic gut microbiota. This ensures that an increasing number of pharmaceuticals are first exposed to the gut microbiota and their
associated collection of metabolic enzymes with the potential for relevant microbiome–drug interactions highest in this region. The fate of drugs
following oral ingestion is most often considered, but parenteral routes can still lead to gut microbiome–drug interactions, for example, via the
splanchnic circulation and bilary excretion. Enterohepatic circulation is an important consideration in this regard, as is the potential for an indirect
impact via microbial regulation of hepatic drug metabolism.
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to improve barrier function (Wlodarska et al., 2017).
Gut-derived microbial metabolites such as propionate,
whose production could be stimulated by prebiotics, can
also exert protective effects on blood-brain barrier
integrity (Hoyles et al., 2018c). Given the importance
of intestinal and blood-brain barrier permeability for
health and disease (Bischoff et al., 2014; Kelly et al.,
2015), this strategy could be combined with the selec-
tion of at-risk or compromised individuals to improve
treatment outcomes.
X. Summary, Conclusions, and Perspectives
The gut microbiome can have a wide variety of direct
and indirect effects on the metabolism of pharmaceuti-
cals, dietary compounds, and environmental chemicals.
The pharmacomicrobiomic web portal currently lists over 90
examples of such chemicals (http://pharmacomicrobiomics.
com/view/chemical/). Although we have been aware of isolat-
ed, but clinically relevant examples for a number of years,
most commentators agree that the current bank of known
reactions is likely to be expanded greatly in future years. For
drug metabolism alone, the implications of microbial bio-
transformation or other indirect actions of gut bacteria are
hugely significant because it results in the activation or
inactivation of drugs and often generates byproducts that are
toxic to the host (Fig. 8).
An increased focus on this important area comes at a
time when sequencing studies have identified gut
microbiome alterations inmany of the disorders treated
by these same drugs. The reciprocal nature of these
microbe–drug interactions has also been demonstrated
with many of these therapeutic agents also modifying
the composition and function of the gut microbiome
(see Table 3), although increased application of tech-
niques to study both microbial transcriptional activities
and metabolic profiles is warranted (Carmody and
Turnbaugh, 2014). Taken together, this paints a com-
plex picture, and whereas a research framework is
being put in place, cross-disciplinary input and increased
attention from the scientific community are required to
address the many outstanding questions in this field
(see Table 4) and to achieve a more comprehensive
view of pharmacology (Saad et al., 2012; Carmody and
Turnbaugh, 2014). We can take encouragement in
these efforts from recent observations regarding the
importance of gut microbiome composition and the
response to cancer therapeutic drugs (Jobin, 2018). If
this can even be partially replicated across the range of
disorders discussed above, themove toward the practice
of precision, personalized medicine may well be expe-
dited by incorporation of microbiome research.
Although there are many examples of remediation
opportunities, we should not neglect the prophylactic
power of diet to help sculpt the diversity that is
necessary in a healthy gut microbiome (Shanahan
et al., 2017).We have noted above a number of instances
in which diet–microbe–host interactions can lead to
adverse consequences. Indeed, the prescription of die-
tary modifications is also now being considered in a
number of disease areas, including psychiatry (Jacka,
2017), as are other lifestyle factors such as exercise,
which is also known to improve gut microbiota profiles
(O’Sullivan et al., 2015). Stress exposure is also an
important consideration, particularly during the ex-
tremes of life when the gut microbiota is more chaotic
and vulnerable. Although there are many reports of
elevated or decreased circulating levels of microbiome-
associated metabolites in pathologic states, there re-
mains an incomplete understanding of their functional
important in the absence of disease. Defining normal
physiologic ranges and toxic concentrations is an im-
portant objective before interventions designed to
remove specific bacteria and/or their associated func-
tions from the human gut microbiome can be effectively
implemented. Neither should we ignore the other
human microbial ecological niches. For example, al-
though we have focused above on the gut microbiome,
microbicide efficacy in African women has been linked
to vaginal microbiome characteristics, with tenofovir
being depleted by bacterial metabolism (Klatt et al.,
2017). Also neglected to date is the gut mycobiome, and
there are indications that our intestinal fungi are an
important component of host–microbe interactions of
relevance to immune homeostasis and inflammatory
disorders (Leonardi et al., 2018) and stress-related
disorders such as irritable bowel syndrome (Botschuijver
et al., 2017).
As our knowledge of the gut microbiome continues to
increase and the balance shifts from new discoveries to
mechanistic insights, so too does our appreciation that
virtually all aspects of host physiology need to be
TABLE 4
Outstanding questions in pharmacomicrobiomics
Key Questions
Do disease-associated microbiomes impact on bacterial enzyme expression and/or activity to dysregulate xenobiotic metabolism?
What is the impact of extreme of life microbiome variation on pharmacokinetics and pharmacodynamics?
Can we unravel disease vs. drug-induced contributions to microbiome alterations?
Can the use of microbiome composition to predict therapeutic response be incorporated into clinical practice?
Can we identify bacteria- and/or enzyme-specific host–microbe interactions for subsequent therapeutic targeting?
Can we compile and systematically evaluate currently unexplained aberrant pharmacokinetic observations?
Can diet be used to beneficially tune microbial xenobiotic metabolism?
Can we differentiate between effects of acute and long-term exposure to xenobiotics on the gut microbiome?
Should we re-evaluate the guidelines for coadministration of antibiotics?
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reconsidered in light of reciprocal host–microbiome
interactions. It is only now logical to include the broad
metabolic capacity of the gut microbiome within funda-
mental principles of pharmacokinetics and pharmaco-
dynamics, the difficulty in rationally manipulating the
chemical biotransformations by unknown enzymes and
members of the gut microbiome notwithstanding. The
future practice of precision medicinemay depend on our
ability to successfully navigate the challenges that lie
ahead and incorporate a more microbial perspective
into clinical guidelines and applications.
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